Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That dead matter has to be absorbed by the body at some point. How long does that take?
Yahoo uses closing price of the first trading day of the year it looks like.
I don't think it will take that long. Once approved and Eden comes on line, additional trials will be started and the primary measure will be tumor size reduction which happens fairly rapidly.
That is not what Yahoo chart shows. According to that chart AVXL is about even YTD.
That was three years ago. Maybe you should consider turning loose from that.
Because Ihub policy is to let the readers determine what is truth and what is nonsense.
A mod's job is to enforce the TOU and nothing more.
I would also point out that personal attacks are a violation of the TOU.
Gosh. Sounds like a crisis alright.
I feel your pain.
Apparently BS has superior anti-cancer efficacy.
Not on any board I moderate. I can see my ignores but no one else's.
So you are suggesting a buyout>>> A real possibility if the price is right.
That is the down side of being a mod. You really shouldn't put anyone on ignore. Which means you have to read all the id10ts.
The difference being that any amyloid reduction, and there seems to be some along with Tau, is secondary MOA, not primary as in the other drugs.
Specials and approved are very different categories.
For a start there will be much more awareness of the approved treatment.
You obviously haven't looked at the "supplements" market.
The days of con artists selling snake oil to unsuspecting and desperate patients are over.
Sometimes BP pays big bucks for Phase 2 drug candidates, in the billions of $. There is no immediate payback there either and a lot higher risk than NWBO at this point.
It's called investing for the future. In the case of NWBO I think it will be called not wanting to be left behind. NWBO patents are worth a lot of money once the treatment is approved. I think those patents will make it more difficult for other companies to enter the DC space with any capacity.
Since an approval in the UK would allow patients from all over the world to seek treatment, I suspect there will be more than enough people that have the money to pay for the treatment to keep the folks at Sawston busy while Eden is being certified.
If $200,000 is what stood between me and a chance to survive GBM I'd willingly sell my house and move into a cheap apartment if that's what it took to have a chance at living.
Recycling at it's best.
You make several assumptions to support your assertions. The most obvious is there is no deal offered because there is no deal.
Has it occurred to you that maybe the company is willing to wait till after approval when it will have much more leverage in making a deal?
Then there was a recent placement that brought about $3 mil into the company. Why do you assume that other such deals can not be made as needed?
After all, the company has survived a very long time under exceptionally difficult circumstances, why would a few more months suddenly be a big issue? Management knows how to keep the company alive and moving forward.
Once approval is granted the company can immediately start getting revenues by license agreements. That would solve the reimbursement issue that you raise, assuming of course that it is a real issue.
The amount of dilution on a percentage basis is minor given the OS is 1.2billion shares. Compared to the value of making a deal post approval that amount of dilution is trivial.
Management keeps selling shares (not dumping) to fund the company as it nears approval, revenues, and access to much better funding terms.
The other choice is most likely BK.
As to the question of whether that is enough to suppress the share price, I'll let each person come to their own conclusion about that.
Yuk yuk.
Patience Grasshopper. 😉
I have much more faith in Anavex getting approved than I do in you ever posting something worthwhile.
That 2500 quote volume is a FINRA rule for share price between 0.20 and 0.5099.
Every member entering quotations in any inter-dealer quotation system that permits quotation updates on a real-time basis must enter and honor those quotations for at least the minimum size defined in the table below. In this regard, it is the member's responsibility to determine the minimum size requirement applicable to its quotation. Depending on the price level of the quotation, a different minimum size can apply to each side of the market being quoted by the member in a given security.
Price (Bid or Offer) Minimum Quote Size
0.0001–0.0999 10,000
0.10-0.1999 5,000
0.20–0.5099 2,500
0.51–0.9999 1,000
1.00–174.99 100
175.00+ 1
Excuse me, but I don't see how that is any more intimidation than the usual much more effective constant verbal attacks I see on the boards. In fact, you have to make an effort to see the number of follows a poster has. I suspect most people don't bother. I only see that when I'm looking to see a posters posting history when I'm trying to get a sense of where a poster is coming from.
Both follows and ignores are imperfect measures by a long shot. Having said that, they have a little value.
Of the follows I have, about 15 or so have been by people that send a message saying they like what I post and think they are worthwhile. I have no idea where the rest came from.
Like that.
I see it as a way to get a sense of how a person is regarded overall. Just as the followed number is vaguely related to a similar evaluation.
Although, I have had a number of follows that came with a request to give a follow to that person in a reciprocal way. Mostly from aliases I have never seen before. So I am pretty skeptical of the follow number.
There is a lot of commonality in submissions to the various agencies. However, they are still separate documents and do require significant work for each one.
Aside from Module 1, submission teams should be happy to hear that Modules 2, 3, 4, and 5 are similar between FDA and EMA submissions. The US and Europe are two of the most similar regions in the world when it comes to their submission requirements, again thanks to ICH guidance on summary documents and submission format.
The main differences discussed in this article are really the exceptions, so we can reframe our approach to assume that 75% or more of the compilation can be conducted simultaneously. It is important to remember that small details can become big headaches in these large, technical documents. As such, careful planning is pivotal to gain an understanding of where the risks and opportunities lie.
Congratulations George. You got one right. That is one in a row. Good luck tomorrow.
About 2 1/2 years.
I get that. What I was asking for was a statistic not for any control. How is that any different from seeing the number of followers?
There is a 5th force in physics. It is the attractive force that binds morons together.
If we are adding access, the one I would like to see is the number of ignores a given poster has acquired. Perhaps under the profile statistics.
To me that would be more useful than the number of follows.
There are those folks that like what they do and will do it as long as their health will allow them to do it.
Approval in the UK will solve most of those items.
AFAIK the EDEN hardware is not available for testing. Didn't the company say that they had made final changes to the design and were ordering hardware?
The baseline for brain loss was Alzheimer's subjects.
There was no comparison to the normal rate of brain loss due to aging. So, we don't know if the rate of loss was reduced to that of normal age related loss, possibly better, or worse than normal but not as bad as those with AD.
I'm curious as to how an interim analysis would introduce additional bias into the final results. For that to occur I would assume that the results of the interim analysis would have to be communicated back to CRO at least.
If the analysis was kept within the company and not communicated to the CRO and or the subjects, I don't see how there would be bias introduced.
Am I missing something?
The celestial finger of fate in that one.
“Put all your eggs in one basket—and watch that basket.” Andrew Carnegie.
That is but one line from the overall speech.
Here is a bit more from that same speech.
To summarize what I have said: Aim for the highest; never enter a bar-room; do not touch liquor, or, if at all, only at meals; never endorse beyond your surplus cash fund; make the firm’s interest yours; break orders always to save owners; concentrate; put all your eggs in one basket, and watch that basket; keep expenditure always within revenue; lastly, be not be impatient, for, as Emerson says, “no one can cheat you out of ultimate success but yourselves.”
The reality is NWBO is small potatoes in the overall scheme of things. The SEC is after bigger fish. There needs to be no other explanation than that.
If NWBO gets the case past discovery the SEC might start to pay attention. If NWBO gets a civil result the SEC will no doubt look at that and consider bringing a case against the civil defendants. If the SEC can develop a case they will refer it to the DOJ for prosecution if the SEC can't get a consent agreement that it likes.
The SEC has no criminal authority. All it can do is levy civil fines and those only if the entity agrees to the fine, otherwise the case goes to the DOJ for prosecution.
What is the difference between the mabs and Blarcamesine?
The mabs have been approved by the FDA.